A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at UC Davis
- Dates
- study startedcompletion around
- Principal Investigator
- by Emanual Maverakis (ucdavis)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Emanual Maverakis (ucdavis)
Professor, Dermatology, School of Medicine. Authored (or co-authored) 216 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- ID
- NCT05372419
- Phase
- Phase 3 Atopic Dermatitis (Eczema) Research Study
- Study Type
- Interventional
- Participants
- Expecting 80 study participants
- Last Updated